UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $68.58 Million Stock Position in DaVita Inc. $DVA

Key Points

• UBS AM has reduced its stock holdings in DaVita Inc. by 3.8%, owning approximately $68.58 million worth of shares after selling 17,755 shares in the first quarter.
• DaVita reported $2.95 earnings per share (EPS) for the last quarter, surpassing estimates and showing a 6.1% year-over-year revenue increase.
• Several institutional investors increased their stakes in DaVita, with notable increases from UMB Bank and the National Pension Service, further indicating strong interest in the company.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC cut its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 3.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 448,291 shares of the company's stock after selling 17,755 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.59% of DaVita worth $68,575,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. UMB Bank n.a. grew its position in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. National Pension Service grew its position in DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after purchasing an additional 84 shares in the last quarter. Copia Wealth Management bought a new stake in DaVita in the 4th quarter worth about $30,000. Y.D. More Investments Ltd bought a new stake in DaVita in the 1st quarter worth about $35,000. Finally, NewEdge Advisors LLC grew its position in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock worth $78,000 after purchasing an additional 88 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

Insider Activity at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.50% of the company's stock.

DaVita Stock Down 0.1%

Shares of NYSE DVA opened at $133.08 on Friday. DaVita Inc. has a one year low of $126.07 and a one year high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. The firm's 50 day simple moving average is $138.45 and its two-hundred day simple moving average is $141.50. The stock has a market capitalization of $9.52 billion, a P/E ratio of 13.09, a PEG ratio of 0.95 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.70 by $0.25. The firm had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business's revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the business earned $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DVA. Truist Financial set a $148.00 target price on shares of DaVita in a research note on Friday, August 8th. Barclays dropped their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Bank of America dropped their target price on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus target price of $158.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.